Search

Your search keyword '"Elser, C"' showing total 143 results
Start Over Author "Elser, C"
143 results on '"Elser, C"'

1. Literacy and Arts-Integrated Science Lessons Engage Urban Elementary Students in Exploring Environmental Issues

Author

Gray, P., Elser, C. F., Klein, J. L., and Rule, A. C.

Abstract

This descriptive case study examined student attitudes, writing skills and content knowledge of urban fourth and fifth graders (6 males, 9 female) during a six-week literacy, thinking skill, and art-integrated environmental science unit. Pre- and post-test questions were used to address knowledge of environmental problems and student environmental actions. Students expressed knowledge and suggestions for positive action of youth through four essays throughout the unit, the final essay being accompanied by a pop-up construction. Writings showed steady growth in number of words, sentences, suggested environmental actions for youth, and instances of discussing consequences and sequels of actions. Students were engaged, collaborative, and reported implementing positive environmental actions.

Published
2016

4. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?

Author

Metcalfe, K, Gronwald, J, Tung, N, Mccuaig, J, Eisen, A, Elser, C, Foulkes, W, Neuhausen, S, Senter, L, Moller, P, Bordeleau, L, Fruscio, R, Velsher, L, Zakalik, D, Olopade, O, Eng, C, Pal, T, Cullinane, C, Couch, F, Kotsopoulos, J, Sun, P, Lubinski, J, Narod, S, Metcalfe K. A., Gronwald J., Tung N. M., McCuaig J. M., Eisen A., Elser C., Foulkes W. D., Neuhausen S. L., Senter L., Moller P., Bordeleau L., Fruscio R., Velsher L., Zakalik D., Olopade O. I., Eng C., Pal T., Cullinane C. A., Couch F. J., Kotsopoulos J., Sun P., Lubinski J., Narod S. A., Metcalfe, K, Gronwald, J, Tung, N, Mccuaig, J, Eisen, A, Elser, C, Foulkes, W, Neuhausen, S, Senter, L, Moller, P, Bordeleau, L, Fruscio, R, Velsher, L, Zakalik, D, Olopade, O, Eng, C, Pal, T, Cullinane, C, Couch, F, Kotsopoulos, J, Sun, P, Lubinski, J, Narod, S, Metcalfe K. A., Gronwald J., Tung N. M., McCuaig J. M., Eisen A., Elser C., Foulkes W. D., Neuhausen S. L., Senter L., Moller P., Bordeleau L., Fruscio R., Velsher L., Zakalik D., Olopade O. I., Eng C., Pal T., Cullinane C. A., Couch F. J., Kotsopoulos J., Sun P., Lubinski J., and Narod S. A.

Abstract

Background: The purpose of this study was to estimate the cumulative risks of all cancers in women from 50 to 75 years of age with a BRCA1 or BRCA2 pathogenic variant. Methods: Participants were women with BRCA1 or BRCA2 pathogenic variants from 85 centers in 16 countries. Women were eligible if they had no cancer before the age of 50 years. Participants completed a baseline questionnaire and follow-up questionnaires every 2 years. Women were followed from age 50 until a diagnosis of cancer, death, age 75, or last follow-up. The risk of all cancers combined from age 50 to 75 was estimated using the Kaplan-Meier method. Results: There were 2211 women included (1470 BRCA1 and 742 BRCA2). There were 379 cancers diagnosed in the cohort between 50 and 75 years. The actuarial risk of any cancer from age 50 to 75 was 49% for BRCA1 and 43% for BRCA2. Breast (n = 186) and ovarian (n = 45) were the most frequent cancers observed. For women who had both risk-reducing mastectomy and bilateral salpingo-oophorectomy before age 50, the risk of developing any cancer between age 50 and 75 was 9%. Conclusion: Women with a BRCA1 or BRCA2 pathogenic variant have a high risk of cancer between the ages of 50 and 75 years and should be counselled appropriately.

Published
2022

5. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation

Author

Xia, Y, Gronwald, J, Karlan, B, Lubinski, J, Mccuaig, J, Brooks, J, Moller, P, Eisen, A, Sun, S, Senter, L, Bordeleau, L, Neuhausen, S, Singer, C, Tung, N, Foulkes, W, Sun, P, Narod, S, Kotsopoulos, J, Yerushalmi, R, Fruscio, R, Rastelli, A, Zovato, S, Hyder, Z, Huzarski, T, Cybulski, C, Sweet, K, Wood, M, Mckinnon, W, Elser, C, Pal, T, Wiesner, G, Friedman, E, Meschino, W, Snyder, C, Metcalfe, K, Poll, A, Gojska, N, Warner, E, Kim, R, Rosen, B, Demsky, R, Ainsworth, P, Panabaker, K, Steele, L, Saal, H, Serfas, K, Panchal, S, Cullinane, A, Reilly, R, Blum, J, Kwong, A, Rayson, D, Isaacs, C, Ramón y Cajal, T, Dungan, J, Cohen, S, Xia Y. Y., Gronwald J., Karlan B., Lubinski J., McCuaig J. M., Brooks J., Moller P., Eisen A., Sun S., Senter L., Bordeleau L., Neuhausen S. L., Singer C. F., Tung N., Foulkes W. D., Sun P., Narod S. A., Kotsopoulos J., Yerushalmi R., Fruscio R., Rastelli A., Zovato S, Hyder Z., Huzarski T., Cybulski C, Sweet K., Wood M., McKinnon W., Elser C., Pal T., Wiesner G., Friedman E., Meschino W., Snyder C., Metcalfe K., Poll A., Gojska N., Warner E., Kim R. H., Rosen B., Demsky R., Ainsworth P., Panabaker K., Steele L., Saal H., Serfas K., Panchal S., Cullinane A., Reilly R. E., Blum J. L., Kwong A., Cybulski C., Rayson D., Isaacs C., Ramón y Cajal T., Dungan J., Cohen S., Xia, Y, Gronwald, J, Karlan, B, Lubinski, J, Mccuaig, J, Brooks, J, Moller, P, Eisen, A, Sun, S, Senter, L, Bordeleau, L, Neuhausen, S, Singer, C, Tung, N, Foulkes, W, Sun, P, Narod, S, Kotsopoulos, J, Yerushalmi, R, Fruscio, R, Rastelli, A, Zovato, S, Hyder, Z, Huzarski, T, Cybulski, C, Sweet, K, Wood, M, Mckinnon, W, Elser, C, Pal, T, Wiesner, G, Friedman, E, Meschino, W, Snyder, C, Metcalfe, K, Poll, A, Gojska, N, Warner, E, Kim, R, Rosen, B, Demsky, R, Ainsworth, P, Panabaker, K, Steele, L, Saal, H, Serfas, K, Panchal, S, Cullinane, A, Reilly, R, Blum, J, Kwong, A, Rayson, D, Isaacs, C, Ramón y Cajal, T, Dungan, J, Cohen, S, Xia Y. Y., Gronwald J., Karlan B., Lubinski J., McCuaig J. M., Brooks J., Moller P., Eisen A., Sun S., Senter L., Bordeleau L., Neuhausen S. L., Singer C. F., Tung N., Foulkes W. D., Sun P., Narod S. A., Kotsopoulos J., Yerushalmi R., Fruscio R., Rastelli A., Zovato S, Hyder Z., Huzarski T., Cybulski C, Sweet K., Wood M., McKinnon W., Elser C., Pal T., Wiesner G., Friedman E., Meschino W., Snyder C., Metcalfe K., Poll A., Gojska N., Warner E., Kim R. H., Rosen B., Demsky R., Ainsworth P., Panabaker K., Steele L., Saal H., Serfas K., Panchal S., Cullinane A., Reilly R. E., Blum J. L., Kwong A., Cybulski C., Rayson D., Isaacs C., Ramón y Cajal T., Dungan J., and Cohen S.

Abstract

Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women with BRCA mutations. Methods A total of 1733 matched pairs were included in this analysis. Women were matched according to year of birth, date of study entry, country of residence, BRCA mutation type and history of breast cancer. Detailed information on hormonal, reproductive and lifestyle exposures were collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with each contraceptive exposure. Results Ever use of any contraceptive was significantly associated with reduced risk of ovarian cancer (OR = 0.62; 95% CI 0.52–0.75; P < 0.0001), which was driven by significant inverse associations with oral contraceptives (OR = 0.66; 95% CI 0.54–0.79; P < 0.0001) and contraceptive implants (OR = 0.30; 95% CI 0.12–0.73; P = 0.008). We observed a similar effect with use of injections (OR = 0.37; 95% CI 0.10–1.38; P = 0.14), but this did not achieve significance. No significant associations were observed between patterns of intrauterine device use and risk of ovarian cancer. Conclusions These findings support a protective effect of oral contraceptives and implants on risk of ovarian cancer among women with BRCA mutations. The possible protective effect of injections requires further evaluation.

Published
2022

6. The effect of geriatric assessment and management on grade 3-5 treatment toxicity: results of the 5C study

Author

Mariano, C., primary, Puts, M., additional, Alqurini, N., additional, Strohschein, F., additional, Koneru, R., additional, Szumacher, E., additional, Monette, J., additional, Hsu, T., additional, Brennenstuhl, S., additional, McLean, B., additional, Wills, A., additional, Berger, A., additional, Amir, E., additional, Romanovsky, L., additional, Li, A., additional, Mehta, R., additional, Krzyzanowska, M., additional, Elser, C., additional, Jang, R., additional, Prica, A., additional, Wan-Chow-Wah, D., additional, Pitters, E., additional, Emmenegger, U., additional, Menjak, I., additional, Bergman, S., additional, Lemonde, M., additional, Breunis, H., additional, Krahn, M., additional, Beland, F., additional, and Alibhai, S., additional

Published
2022
Full Text
View/download PDF

7. The impact of the COVID-19 pandemic on quality of life, health care use and mortality in older adults in the 5C study of geriatric assessment and management: secondary analysis

Author

Pitters, E., primary, Puts, M., additional, Alqurini, N., additional, Strohschein, F., additional, Koneru, R., additional, Szumacher, E., additional, Mariano, C., additional, Monette, J., additional, Hsu, T., additional, Brennenstuhl, S., additional, McLean, B., additional, Wills, A., additional, Berger, A., additional, Amir, E., additional, Romanovsky, L., additional, Li, A., additional, Mehta, R., additional, Krzyzanowska, M., additional, Elser, C., additional, Jang, R., additional, Prica, A., additional, Wan-Chow-Wah, D., additional, Emmenegger, U., additional, Menjak, I., additional, Bergman, S., additional, Lemonde, M., additional, Krahn, M., additional, Beland, F., additional, Breunis, H., additional, and Alibhai, S., additional

Published
2022
Full Text
View/download PDF

8. Falls occurring in older adults in the 5C trial undergoing cancer treatment

Author

Breunis, H., primary, Puts, M., additional, Alqurini, N., additional, Strohschein, F., additional, Koneru, R., additional, Szumacher, E., additional, Mariano, C., additional, Monette, J., additional, Hsu, T., additional, Brennenstuhl, S., additional, McLean, B., additional, Wills, A., additional, Berger, A., additional, Amir, E., additional, Romanovsky, L., additional, Li, A., additional, Mehta, R., additional, Krzyzanowska, M., additional, Elser, C., additional, Jang, R., additional, Prica, A., additional, Wan-Chow-Wah, D., additional, Pitters, E., additional, Emmenegger, U., additional, Menjak, I., additional, Bergman, S., additional, Lemonde, M., additional, Krahn, M., additional, Beland, F., additional, and Alibhai, S., additional

Published
2022
Full Text
View/download PDF

9. Recommendations and adherence to recommendations made based on a comprehensive geriatric assessment for Canadian older adults with cancer: Results of the 5C trial

Author

Puts, M., primary, Alqurini, N., additional, Strohschein, F., additional, Berger, A., additional, Romanovsky, L., additional, Monette, J., additional, Mehta, R., additional, Li, A., additional, Wan-Chow-Wah, D., additional, Hsu, T., additional, Brennenstuhl, S., additional, Koneru, R., additional, Szumacher, E., additional, Mariano, C., additional, McLean, B., additional, Wills, A., additional, Amir, E., additional, Krzyzanowska, M., additional, Elser, C., additional, Jang, R., additional, Prica, A., additional, Pitters, E., additional, Emmenegger, U., additional, Menjak, I., additional, Bergman, S., additional, Lemonde, M., additional, Breunis, H., additional, Beland, F., additional, Krahn, M., additional, and Alibhai, S., additional

Published
2022
Full Text
View/download PDF

10. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

Author

Stjepanovic, N, Lubinski, J, Moller, P, Randall Armel, S, Foulkes, W, Tung, N, Neuhausen, S, Kotsopoulos, J, Sun, P, Sun, S, Eisen, A, Narod, S, Senter, L, Couch, C, Fruscio, R, Weitzel, J, Olopade, O, Singer, C, Pal, T, Huzarski, T, Cybulski, C, Sweet, K, Zakalik, D, Wood, M, Mckinnon, W, Elser, C, Wiesner, G, Friedman, E, Meschino, W, Snyder, C, Metcalfe, K, Poll, A, Warner, E, Kim, R, Demsky, R, Ainsworth, P, Steele, L, Saal, H, Serfas, K, Panchal, S, Cullinane, C, Reilly, R, Blum, J, Kwong, A, Rayson, D, Cajal, T, Dungan, J, Yerushalmi, R, Ginsburg, O, Schraeder, I, Cohen, S, Lemirelemire, E, Zovato, S, Rastelli, A, Gronwald, J, Mccuaig, J, Karlan, B, Bordeleau, L, Stjepanovic N., Lubinski J., Moller P., Randall Armel S., Foulkes W. D., Tung N., Neuhausen S. L., Kotsopoulos J., Sun P., Sun S., Eisen A., Narod S. A., Senter L., Couch C. E. F., Fruscio R., Weitzel J. N., Olopade O., Singer C. F., Pal T., Huzarski T., Cybulski C., Sweet K., Zakalik D., Wood M., McKinnon W., Elser C., Wiesner G., Friedman E., Meschino W., Snyder C., Metcalfe K., Poll A., Warner E., Kim R., Demsky R., Ainsworth P., Steele L., Saal H., Serfas K., Panchal S., Cullinane C. A., Reilly R. E., Blum J. L., Kwong A., Rayson D., Cajal T. R., Dungan J., Yerushalmi R., Ginsburg O., Schraeder I., Cohen S., LemireLemire E., Zovato S., Rastelli A., Gronwald J., McCuaig J., Karlan B., Bordeleau L., Stjepanovic, N, Lubinski, J, Moller, P, Randall Armel, S, Foulkes, W, Tung, N, Neuhausen, S, Kotsopoulos, J, Sun, P, Sun, S, Eisen, A, Narod, S, Senter, L, Couch, C, Fruscio, R, Weitzel, J, Olopade, O, Singer, C, Pal, T, Huzarski, T, Cybulski, C, Sweet, K, Zakalik, D, Wood, M, Mckinnon, W, Elser, C, Wiesner, G, Friedman, E, Meschino, W, Snyder, C, Metcalfe, K, Poll, A, Warner, E, Kim, R, Demsky, R, Ainsworth, P, Steele, L, Saal, H, Serfas, K, Panchal, S, Cullinane, C, Reilly, R, Blum, J, Kwong, A, Rayson, D, Cajal, T, Dungan, J, Yerushalmi, R, Ginsburg, O, Schraeder, I, Cohen, S, Lemirelemire, E, Zovato, S, Rastelli, A, Gronwald, J, Mccuaig, J, Karlan, B, Bordeleau, L, Stjepanovic N., Lubinski J., Moller P., Randall Armel S., Foulkes W. D., Tung N., Neuhausen S. L., Kotsopoulos J., Sun P., Sun S., Eisen A., Narod S. A., Senter L., Couch C. E. F., Fruscio R., Weitzel J. N., Olopade O., Singer C. F., Pal T., Huzarski T., Cybulski C., Sweet K., Zakalik D., Wood M., McKinnon W., Elser C., Wiesner G., Friedman E., Meschino W., Snyder C., Metcalfe K., Poll A., Warner E., Kim R., Demsky R., Ainsworth P., Steele L., Saal H., Serfas K., Panchal S., Cullinane C. A., Reilly R. E., Blum J. L., Kwong A., Rayson D., Cajal T. R., Dungan J., Yerushalmi R., Ginsburg O., Schraeder I., Cohen S., LemireLemire E., Zovato S., Rastelli A., Gronwald J., McCuaig J., Karlan B., and Bordeleau L.

Abstract

Purpose: It is not known whether the risk of breast cancer among BRCA1 and BRCA2 mutation carriers after age 60 is high enough to justify intensive screening or prophylactic surgery. Thus, we conducted a prospective analysis of breast cancer risk in BRCA1 and BRCA2 mutation carriers from age 60 until age 80. Methods: Subjects had no history of cancer and both breasts intact at age 60 (n = 699). Women were followed until a breast cancer diagnosis, prophylactic bilateral mastectomy or death. We calculated the annual cancer rate and cumulative incidence of breast cancer (invasive and in situ) from age 60 to age 80. We assessed the associations between hormone replacement therapy, family history of breast cancer and bilateral oophorectomy and breast cancer risk. Results: Over a mean follow-up of 7.9 years, 61 invasive and 20 in situ breast cancers were diagnosed in the cohort. The mean annual rate of invasive breast cancer was 1.8% for BRCA1 mutation carriers and 1.7% for BRCA2 mutation carriers. The cumulative risk of invasive breast cancer from age 60 to 80 was 20.1% for women with a BRCA1 mutation and was 17.3% for women with a BRCA2 mutation. Hormone replacement therapy, family history and oophorectomy were not associated with breast cancer risk. Conclusions: Findings from this large prospective study indicate that the risk of developing breast cancer remains high after age 60 in both BRCA1 and BRCA2 mutation carriers. These findings warrant further evaluation of the role of breast cancer screening in older mutation carriers.

Published
2021

11. Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery.

Author

Shickh, S, Hirjikaka, D, Clausen, M, Kodida, R, Mighton, C, Reble, E, Sam, J, Panchal, S, Aronson, M, Graham, T, Armel, SR, Glogowski, E, Elser, C, Eisen, A, Carroll, JC, Shuman, C, Seto, E, Baxter, NN, Scheer, A, Shastri-Estrada, S, Feldman, G, Thorpe, KE, Schrader, KA, Lerner-Ellis, J, Kim, RH, Faghfoury, H, Bombard, Y, Shickh, S, Hirjikaka, D, Clausen, M, Kodida, R, Mighton, C, Reble, E, Sam, J, Panchal, S, Aronson, M, Graham, T, Armel, SR, Glogowski, E, Elser, C, Eisen, A, Carroll, JC, Shuman, C, Seto, E, Baxter, NN, Scheer, A, Shastri-Estrada, S, Feldman, G, Thorpe, KE, Schrader, KA, Lerner-Ellis, J, Kim, RH, Faghfoury, H, and Bombard, Y

Abstract

INTRODUCTION: The high demand for genetic tests and limited supply of genetics professionals has created a need for alternative service delivery models. Digital tools are increasingly being used to support multiple points in the genetic testing journey; however, none are transferable across multiple clinical specialties and settings nor do they encompass the entire trajectory of the journey. We aim to evaluate the effectiveness of the Genetics Adviser, an interactive, patient-facing, online digital health tool that delivers pre-test counselling, provides support during the waiting period for results, and returns results with post-test counselling, encompassing the entire patient genetic testing journey. METHODS AND ANALYSIS: We will compare the Genetics Adviser paired with a brief genetic counselling session to genetic counselling alone in a randomised controlled trial. One hundred and forty patients who previously received uninformative genetic test results for their personal and family history of cancer will be recruited from familial cancer clinics in Toronto and offered all clinically significant results from genomic sequencing. Participants randomised into the intervention arm will use the Genetics Adviser to learn about genomic sequencing, receive pre-test counselling, support during the waiting period and results, supplemented with brief counselling from a genetic counsellor. Participants in the control arm will receive standard pre-test and post-test counselling for genomic sequencing from a genetic counsellor. Our primary outcome is decisional conflict following pre-test counselling from the Genetics Adviser+genetic counsellor or counsellor alone. Secondary outcomes include: knowledge, satisfaction with decision-making, anxiety, quality of life, psychological impact of results, empowerment, acceptability and economic impact for patients and the health system. A subset of patients will be interviewed to assess user experience. ETHICS AND DISSEMINATION: This

Published
2022

12. The Risks of Breast and Ovarian Cancer Associated with the Ashkenazi Jewish Founder Allele BRCA2 6174delT

Author

Finch, A, Metcalfe, K, Akbari, M, Friedman, E, Tung, N, Rosen, B, Eisen, A, Karlan, B, Foulkes, W, Neuhausen, S, Senter, L, Mckinnon, W, Elser, C, Sun, P, Narod, S, Fruscio, R, Finch, Amy, Metcalfe, Kelly, Akbari, Mohammad, Friedman, Eitan, Tung, Nadine, Rosen, Barry, Eisen, Andrea, Karlan, Beth, Foulkes, William, Neuhausen, Susan L, Senter, Leigha, McKinnon, Wendy, Elser, Christine, Sun, Ping, Narod, Steven A, Fruscio Robert, Finch, A, Metcalfe, K, Akbari, M, Friedman, E, Tung, N, Rosen, B, Eisen, A, Karlan, B, Foulkes, W, Neuhausen, S, Senter, L, Mckinnon, W, Elser, C, Sun, P, Narod, S, Fruscio, R, Finch, Amy, Metcalfe, Kelly, Akbari, Mohammad, Friedman, Eitan, Tung, Nadine, Rosen, Barry, Eisen, Andrea, Karlan, Beth, Foulkes, William, Neuhausen, Susan L, Senter, Leigha, McKinnon, Wendy, Elser, Christine, Sun, Ping, Narod, Steven A, and Fruscio Robert

Abstract

Approximately 1% of the Ashkenazi Jewish population carries the BRCA2 6174delT (c.5946del) pathogenic variant. It is important to have accurate knowledge of the risks of breast and ovarian cancer associated with this specific variant so that women may be counseled accordingly. In this prospective study, we estimated the risks of breast and ovarian cancer associated with the 6174delT variant compared with the risks for other pathogenic variants in the BRCA2 gene. The annual risk for developing breast cancer was significantly lower in 246 women who carried the 6174delT variant compared with 721 non-Jewish women who carried a variant at any other locus in BRCA2 (1.2% per year vs. 2.4% per year, p = 0.003). We estimated the cumulative risk of breast cancer from age 30 to 70 to be 39% for carriers of the BRCA2 6174delT variant and 61% for carriers of other BRCA2 variants. The annual risk for ovarian or fallopian tube cancer was 0.51% per year for the 233 women who carried the 6174delT variant compared to 0.22% per year for the 1128 carriers of other BRCA2 variants; the difference was not significant. Lower risks for breast cancer associated with 6174delT may not impact screening and prevention choices, however, the discussion should be based on accurate risk assessment.

Published
2022

13. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

Author

Stjepanovic N., Lubinski J., Moller P., Randall Armel S., Foulkes W. D., Tung N., Neuhausen S. L., Kotsopoulos J., Sun P., Sun S., Eisen A., Narod S. A., Senter L., Couch C. E. F., Fruscio R., Weitzel J. N., Olopade O., Singer C. F., Pal T., Huzarski T., Cybulski C., Sweet K., Zakalik D., Wood M., McKinnon W., Elser C., Wiesner G., Friedman E., Meschino W., Snyder C., Metcalfe K., Poll A., Warner E., Kim R., Demsky R., Ainsworth P., Steele L., Saal H., Serfas K., Panchal S., Cullinane C. A., Reilly R. E., Blum J. L., Kwong A., Rayson D., Cajal T. R., Dungan J., Yerushalmi R., Ginsburg O., Schraeder I., Cohen S., LemireLemire E., Zovato S., Rastelli A., Gronwald J., McCuaig J., Karlan B., Bordeleau L., Stjepanovic, N, Lubinski, J, Moller, P, Randall Armel, S, Foulkes, W, Tung, N, Neuhausen, S, Kotsopoulos, J, Sun, P, Sun, S, Eisen, A, Narod, S, Senter, L, Couch, C, Fruscio, R, Weitzel, J, Olopade, O, Singer, C, Pal, T, Huzarski, T, Cybulski, C, Sweet, K, Zakalik, D, Wood, M, Mckinnon, W, Elser, C, Wiesner, G, Friedman, E, Meschino, W, Snyder, C, Metcalfe, K, Poll, A, Warner, E, Kim, R, Demsky, R, Ainsworth, P, Steele, L, Saal, H, Serfas, K, Panchal, S, Cullinane, C, Reilly, R, Blum, J, Kwong, A, Rayson, D, Cajal, T, Dungan, J, Yerushalmi, R, Ginsburg, O, Schraeder, I, Cohen, S, Lemirelemire, E, Zovato, S, Rastelli, A, Gronwald, J, Mccuaig, J, Karlan, B, and Bordeleau, L

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Heterozygote, medicine.medical_treatment, Ovariectomy, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, 03 medical and health sciences, Breast cancer screening, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, Humans, Cumulative incidence, Genetic Predisposition to Disease, Prospective Studies, skin and connective tissue diseases, Prospective cohort study, Mastectomy, Aged, Aged, 80 and over, BRCA2 Protein, medicine.diagnostic_test, business.industry, BRCA1 Protein, Incidence, Oophorectomy, Cancer, Hormone replacement therapy (menopause), Middle Aged, BRCA1, medicine.disease, BRCA2, Prophylactic Surgery, 3. Good health, Prospective, 030104 developmental biology, 030220 oncology & carcinogenesis, Mutation, Female, business
Abstract

Purpose: It is not known whether the risk of breast cancer among BRCA1 and BRCA2 mutation carriers after age 60 is high enough to justify intensive screening or prophylactic surgery. Thus, we conducted a prospective analysis of breast cancer risk in BRCA1 and BRCA2 mutation carriers from age 60 until age 80. Methods: Subjects had no history of cancer and both breasts intact at age 60 (n = 699). Women were followed until a breast cancer diagnosis, prophylactic bilateral mastectomy or death. We calculated the annual cancer rate and cumulative incidence of breast cancer (invasive and in situ) from age 60 to age 80. We assessed the associations between hormone replacement therapy, family history of breast cancer and bilateral oophorectomy and breast cancer risk. Results: Over a mean follow-up of 7.9years, 61 invasive and 20 in situ breast cancers were diagnosed in the cohort. The mean annual rate of invasive breast cancer was 1.8% for BRCA1 mutation carriers and 1.7% for BRCA2 mutation carriers. The cumulative risk of invasive breast cancer from age 60 to 80 was 20.1% for women with a BRCA1 mutation and was 17.3% for women with a BRCA2 mutation. Hormone replacement therapy, family history and oophorectomy were not associated with breast cancer risk. Conclusions: Findings from this large prospective study indicate that the risk of developing breast cancer remains high after age 60 in both BRCA1 and BRCA2 mutation carriers. These findings warrant further evaluation of the role of breast cancer screening in older mutation carriers.

Published
2020

14. Comprehensive geriatric assessment and management for Canadian elders with Cancer: The 5C study

Author

Puts, M., primary, Alqurini, N., additional, Strohschein, F., additional, Mariano, C., additional, Monette, J., additional, Wan-Chow-Wah, D., additional, Szumacher, E., additional, Koneru, R., additional, Mehta, R., additional, Li, A., additional, Hsu, T., additional, Brennenstuhl, S., additional, McLean, B., additional, Wills, A., additional, Amir, E., additional, Krzyzanowska, M., additional, Elser, C., additional, Pitters, E., additional, Breunis, H., additional, Berger, A., additional, Romanovsky, L., additional, and Alibhai, S., additional

Published
2021
Full Text
View/download PDF

18. Quality of life drives patients' preferences for secondary findings from genomic sequencing

Author

Mighton, C, Carlsson, L, Clausen, M, Casalino, S, Shickh, S, McCuaig, L, Joshi, E, Panchal, S, Semotiuk, K, Ott, K, Elser, C, Eisen, A, KiM, RH, Lerner-Ellis, J, Carroll, JC, Glogowski, E, Schrader, K, Bombard, Y, Mighton, C, Carlsson, L, Clausen, M, Casalino, S, Shickh, S, McCuaig, L, Joshi, E, Panchal, S, Semotiuk, K, Ott, K, Elser, C, Eisen, A, KiM, RH, Lerner-Ellis, J, Carroll, JC, Glogowski, E, Schrader, K, and Bombard, Y

Abstract

There is growing impetus to include measures of personal utility, the nonmedical value of information, in addition to clinical utility in health technology assessment (HTA) of genomic tests such as genomic sequencing (GS). However, personal utility and clinical utility are challenging to define and measure. This study aimed to explore what drives patients' preferences for hypothetically learning medically actionable and non-medically actionable secondary findings (SF), capturing clinical and personal utility; this may inform development of measures to evaluate patient outcomes following return of SF. Semi-structured interviews were conducted with adults with a personal or family cancer history participating in a trial of a decision aid for selection of SF from genomic sequencing (GS) ( www.GenomicsADvISER.com ). Interviews were analyzed thematically using constant comparison. Preserving health-related and non-health-related quality of life was an overarching motivator for both learning and not learning SF. Some participants perceived that learning SF would help them "have a good quality of life" through informing actions to maintain physical health or leading to psychological benefits such as emotional preparation for disease. Other participants preferred not to learn SF because results "could ruin your quality of life," such as by causing negative psychological impacts. Measuring health-related and non-health-related quality of life may capture outcomes related to clinical and personal utility of GS and SF, which have previously been challenging to measure. Without appropriate measures, generating and synthesizing evidence to evaluate genomic technologies such as GS will continue to be a challenge, and will undervalue potential benefits of GS and SF.

Published
2020

19. Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial

Author

Bombard, Y, Clausen, M, Shickh, S, Mighton, C, Casalino, S, Kim, THM, Muir, SM, Carlsson, L, Baxter, N, Scheer, A, Elser, C, Eisen, A, Panchal, S, Graham, T, Aronson, M, Piccinin, C, Mancuso, T, Semotiuk, K, Evans, M, Carroll, JC, Offit, K, Robson, M, Hamilton, JG, Glogowski, E, Schrader, K, Kim, RH, Lerner-Ellis, J, Thorpe, KE, Laupacis, A, Bombard, Y, Clausen, M, Shickh, S, Mighton, C, Casalino, S, Kim, THM, Muir, SM, Carlsson, L, Baxter, N, Scheer, A, Elser, C, Eisen, A, Panchal, S, Graham, T, Aronson, M, Piccinin, C, Mancuso, T, Semotiuk, K, Evans, M, Carroll, JC, Offit, K, Robson, M, Hamilton, JG, Glogowski, E, Schrader, K, Kim, RH, Lerner-Ellis, J, Thorpe, KE, and Laupacis, A

Abstract

PURPOSE: To evaluate the effectiveness of the Genomics ADvISER (www.genomicsadviser.com) decision aid (DA) for selection of secondary findings (SF), compared with genetic counseling alone. METHODS: A randomized controlled trial (RCT) was conducted to evaluate whether the Genomics ADvISER is superior to genetic counseling when hypothetically selecting SF. Participants were randomized to use the DA followed by discussion with a genetic counselor, or to genetic counseling alone. Surveys were administered at baseline and post-intervention. Primary outcome was decisional conflict. Secondary outcomes were knowledge, preparation for, and satisfaction with decision-making, anxiety, and length of counseling session. RESULTS: Participants (n = 133) were predominantly White/European (74%), female (90%), and ≥50 years old (60%). Decisional conflict (mean difference 0.05; P = 0.60), preparation for decision-making (0.17; P = 0.95), satisfaction with decision (-2.18; P = 0.06), anxiety (0.72; P = 0.56), and knowledge of sequencing limitations (0.14; P = 0.70) did not significantly differ between groups. However, intervention participants had significantly higher knowledge of SF (0.39; P < 0.001) and sequencing benefits (0.97; P = 0.01), and significantly shorter counseling time (24.40 minutes less; P < 0.001) CONCLUSIONS: The Genomics ADvISER did not decrease decisional conflict but reduced counseling time and improved knowledge. This decision aid could serve as an educational tool, reducing in-clinic time and potentially health care costs.

Published
2020

20. CLINICAL AND COST-EFFECTIVENESS OF COMPREHENSIVE GERIATRIC ASSESSMENT AND MANAGEMENT FOR CANADIAN ELDERS WITH CANCER: THE 5C STUDY – INITIAL RECRUITMENT AND IMPLEMENTATION RESULTS

Author

Puts, M., primary, Strohschein, F., additional, Mclean, B., additional, Alqurini, N., additional, Syed, A.T., additional, Amir, E., additional, Béland, F., additional, Berger, A., additional, Bergman, S., additional, Vanderbyl, B., additional, Breunis, H., additional, Elser, C., additional, Emmenegger, U., additional, Fung, S., additional, Hsu, T., additional, Jang, R., additional, Krahn, M., additional, Koneru, R., additional, Kozlowski, N., additional, Krzyzanowska, M., additional, Lemonde, M., additional, Li, A., additional, Mariano, C., additional, Mehta, R., additional, Monette, J., additional, Papadakos, J., additional, Pitters, E., additional, Prica, A., additional, Ray, J., additional, Romanofsky, L., additional, Szumacher, E., additional, Wan-Chow-Wah, D., additional, Langleben, A., additional, and Alibhai, S., additional

Published
2019
Full Text
View/download PDF

23. SIOG2022-0147 - Falls occurring in older adults in the 5C trial undergoing cancer treatment

Author

Breunis, H., Puts, M., Alqurini, N., Strohschein, F., Koneru, R., Szumacher, E., Mariano, C., Monette, J., Hsu, T., Brennenstuhl, S., McLean, B., Wills, A., Berger, A., Amir, E., Romanovsky, L., Li, A., Mehta, R., Krzyzanowska, M., Elser, C., Jang, R., Prica, A., Wan-Chow-Wah, D., Pitters, E., Emmenegger, U., Menjak, I., Bergman, S., Lemonde, M., Krahn, M., Beland, F., and Alibhai, S.

Published
2022
Full Text
View/download PDF

24. SIOG2022-0093 - Recommendations and adherence to recommendations made based on a comprehensive geriatric assessment for Canadian older adults with cancer: Results of the 5C trial

Author

Puts, M., Alqurini, N., Strohschein, F., Berger, A., Romanovsky, L., Monette, J., Mehta, R., Li, A., Wan-Chow-Wah, D., Hsu, T., Brennenstuhl, S., Koneru, R., Szumacher, E., Mariano, C., McLean, B., Wills, A., Amir, E., Krzyzanowska, M., Elser, C., Jang, R., Prica, A., Pitters, E., Emmenegger, U., Menjak, I., Bergman, S., Lemonde, M., Breunis, H., Beland, F., Krahn, M., and Alibhai, S.

Published
2022
Full Text
View/download PDF

25. SIOG2022–0095 - The impact of the COVID-19 pandemic on quality of life, health care use and mortality in older adults in the 5C study of geriatric assessment and management: secondary analysis

Author

Pitters, E., Puts, M., Alqurini, N., Strohschein, F., Koneru, R., Szumacher, E., Mariano, C., Monette, J., Hsu, T., Brennenstuhl, S., McLean, B., Wills, A., Berger, A., Amir, E., Romanovsky, L., Li, A., Mehta, R., Krzyzanowska, M., Elser, C., Jang, R., Prica, A., Wan-Chow-Wah, D., Emmenegger, U., Menjak, I., Bergman, S., Lemonde, M., Krahn, M., Beland, F., Breunis, H., and Alibhai, S.

Published
2022
Full Text
View/download PDF

26. SIOG2022-0094 - The effect of geriatric assessment and management on grade 3-5 treatment toxicity: results of the 5C study

Author

Mariano, C., Puts, M., Alqurini, N., Strohschein, F., Koneru, R., Szumacher, E., Monette, J., Hsu, T., Brennenstuhl, S., McLean, B., Wills, A., Berger, A., Amir, E., Romanovsky, L., Li, A., Mehta, R., Krzyzanowska, M., Elser, C., Jang, R., Prica, A., Wan-Chow-Wah, D., Pitters, E., Emmenegger, U., Menjak, I., Bergman, S., Lemonde, M., Breunis, H., Krahn, M., Beland, F., and Alibhai, S.

Published
2022
Full Text
View/download PDF

27. The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers

Author

Kwang-Pil, Ko, Kim, Shana J, Huzarski, Tomasz, Gronwald, Jacek, Lubinski, Jan, Lynch, Henry T, Armel, Susan, Park, Sue K, Karlan, Beth, Singer, Christian F, Neuhausen, Susan L, Narod, Steven A, Kotsopoulos, Joanne, Snyder, C, Meschino, W, Demsky, R, Ainsworth, P, Panabaker, K, Taylor, M, Couch, F, Manoukian, S, Rappaport, C, Pasini, B, Daly, Mb, Olopade, O, Steele, L, Saal, H, Fallen, T, Wood, M, Mckinnon, W, Lemire, E, Chudley, Ae, Serfas, K, Sweet, K, Bordeleau, L, Elser, C, Panchal, S, Zakalik, D, Vadaparampil, St, Ginsburg, O, Hurst, S, Cullinane, Ca, Reilly, Re, Blum, Jl, Ross, T, Mauer, C, Kwong, A, Cybulski, C, Mccuaig, J, Merajver, S, Friedman, E, Rayson, D, Euhus, D, Foulkes, Wd, Senter, L, Tung, N, Weitzel, Jn, Eisen, A, Metcalfe, K, Eng, C, Pal, T, Evans, G, Moller, P, Rosen, B, and Isaacs, C.

Subjects
Adult, Ovarian Neoplasms, Heterozygote, endocrine system diseases, Incidence, Genes, BRCA2, Smoking, Genes, BRCA1, Middle Aged, BRCA1, BRCA2, Article, breast cancer, ovarian cancer, smoking, Disease Susceptibility, Female, Follow-Up Studies, Humans, Neoplasms, Risk Factors, Mutation, Genes, skin and connective tissue diseases
Abstract

Tobacco smoke is an established carcinogen, but the association between tobacco smoking and cancer risk in BRCA mutation carriers is not clear. The aim of this study was to evaluate prospectively the association between tobacco smoking and cancer incidence in a cohort of BRCA1 and BRCA2 mutation carriers. The study population consisted of unaffected BRCA mutation carriers. Information on lifestyle including smoking histories, reproductive factors, and past medical histories was obtained through questionnaires. Incident cancers were updated biennially via follow-up questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using time-dependent Cox regression models. There were 700 incident cancers diagnosed over 26,711 person-years of follow-up. The most frequent cancers seen in BRCA mutation carriers were breast (n = 428; 61%) and ovarian (n = 109; 15%) cancer. Compared to nonsmokers, (ever) smoking was associated with a modest increased risk of all cancers combined (HR = 1.17; 95%CI 1.01-1.37). Women in the highest group of total pack-years (4.3-9.8) had an increased risk of developing any cancer (HR = 1.27; 95%CI 1.04-1.56), breast cancer (HR = 1.33, 95%CI 1.02-1.75), and ovarian cancer (HR = 1.68; 95%CI 1.06-2.67) compared to never smokers. The associations between tobacco smoking and cancer did not differ by BRCA mutation type or by age at diagnosis. This prospective study suggests that tobacco smoking is associated with a modest increase in the risks of breast and ovarian cancer among women with BRCA1 or BRCA2 mutation.

Published
2018

28. Abstract P1-16-03: Phase II randomized clinical trial (RCT) of metformin (MET) vs placebo (PLAC) in combination with chemotherapy (CXT) in refractory locally advanced (LABC) or metastatic breast cancer (MBC)

Author

Goodwin, PJ, primary, Ennis, M, additional, Cescon, DW, additional, Elser, C, additional, Haq, R, additional, Hamm, CM, additional, Lohmann, AE, additional, Pimentel, I, additional, Chang, MC, additional, Dowling, RJ, additional, and Stambolic, V, additional

Published
2019
Full Text
View/download PDF

33. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations

Author

Bordeleau, L, Lipscombe, L, Lubinski, J, Ghadirian, P, Foulkes, Wd, Neuhausen, S, Ainsworth, P, Pollak, M, Sun, P, Narod, Sa, Hereditary Breast Cancer Clinical Study Group Collaborators: Lynch HT, Eisen, A, Mckinnon, W, Wood, M, Saal, H, Chudley, A, Robidoux, A, Kim Sing, C, Tung, N, Armel, S, Huzarski, T, Provencher, D, Lemire, E, Tulman, A, Llacuachaqui, M, Sweet, K, Gilchrist, D, Karlan, B, Kurz, R, Rosen, B, Demsky, R, Panchal, S, Couch, F, Elser, C, Manoukian, S, Daly, M, Cybulski, C, Gronwald, J, Byrski, T, Olapade, O, Stoppa Lyonnet, D, Weitzel, J, Mclennan, J, Meschino, W, Pasini, Barbara, Singer, C, Dressler, C, Metcalfe, K, Domchek, S, and Isaacs, C.

Subjects
Adult, Oncology, Cancer Research, medicine.medical_specialty, Genes, BRCA2, BRCA1, BRCA2, breast cancer, diabetes, Genes, BRCA1, Antineoplastic Agents, Breast Neoplasms, Risk Assessment, Biochemistry, Article, Diabetes mellitus genetics, Breast cancer, Risk Factors, Internal medicine, Diabetes Mellitus, medicine, Hyperinsulinemia, Humans, Genetic Predisposition to Disease, Risk factor, skin and connective tissue diseases, Aged, Aged, 80 and over, business.industry, Diabetes, Obstetrics and Gynecology, Cancer, Middle Aged, medicine.disease, Risk factors for breast cancer, Case-Control Studies, Mutation, Cancer research, Female, Breast disease, Risk assessment, business
Abstract

Women with a BRCA1 or BRCA2 mutation face a high lifetime risk of breast cancer.1 It is important to identify risk factors for breast cancer among genetically predisposed women, to devise strategies to minimize the risk. Several lines of evidence link diabetes and breast cancer.2,3 Insulin resistance and hyperinsulinemia, which predispose to diabetes, may increase the risk of breast cancer in the general population,4 and hyperinsulinemia may promote the growth of pre-existing breast neoplasms.5 Furthermore, a high body mass index (BMI) is a risk factor for both breast cancer recurrence and for insulin resistance.6–8 It is also of interest to establish whether diabetes (or any of the drugs used to treat diabetes) influences the risk of breast cancer in BRCA carriers. The risk of future diabetes may also be increased in women after a diagnosis of breast cancer.9 This risk may be mediated by common risk factors, such as high BMI or insulin resistance, or diabetes may be a late effect of breast cancer treatment. It is important to explore the impact of these factors on the risk of diabetes in women with BRCA mutations. In this cohort of BRCA carriers, we sought to determine whether diabetes increases the risk of breast cancer in BRCA carriers, and to identify risk factors for diabetes in this high-risk population.

Published
2010

34. P108 - CLINICAL AND COST-EFFECTIVENESS OF COMPREHENSIVE GERIATRIC ASSESSMENT AND MANAGEMENT FOR CANADIAN ELDERS WITH CANCER: THE 5C STUDY – INITIAL RECRUITMENT AND IMPLEMENTATION RESULTS

Author

Puts, M., Strohschein, F., Mclean, B., Alqurini, N., Syed, A.T., Amir, E., Béland, F., Berger, A., Bergman, S., Vanderbyl, B., Breunis, H., Elser, C., Emmenegger, U., Fung, S., Hsu, T., Jang, R., Krahn, M., Koneru, R., Kozlowski, N., Krzyzanowska, M., Lemonde, M., Li, A., Mariano, C., Mehta, R., Monette, J., Papadakos, J., Pitters, E., Prica, A., Ray, J., Romanofsky, L., Szumacher, E., Wan-Chow-Wah, D., Langleben, A., and Alibhai, S.

Published
2019
Full Text
View/download PDF

35. P003 Implementation of High Throughput Parallel Sequencing in a Diagnostic Setting: Multiplexed Amplicon Sequencing of the Breast Cancer Genes BRCA1 and 2

Author

Zogopoulos G, Tomi Pastinen, Sivanandan K, Vaca F, Kinoshita T, Johannes B, Leguis E, Jansen-van der Weide M, Learn L, Godlewski D, Ed Saunders, Montserrat Rué, Vaisman A, de Bock G, Ángel Segura, Sabbaghian N, Mohammad Amin Kerachian, Pelletier S, Metcalfe K, Lilge L, Stockle E, Cheng S, Burger C, Woike A, Michelle Guy, Ragone A, Y. J. Bignon, Bronkhorst Y, Patricia N. Tonin, Lima M, Mieke Kriege, Karsan A, Zweemer R, Prady C, Beattie M, Panchal S, Kathleen Claes, van Zon P, Diane Provencher, Ummels A, Kang I, Shumak R, Arcusa Â, Yosr Hamdi, Alonso Mc, Dolman L, Houssami N, Olivier Delattre, Yannick Bidet, Claude Houdayer, Mercedes Durán, Ganschow P, Isabel Chirivella, Domingo S, Rebsamen M, Giustina Simone, Orland Diez, Chapman J, An tSaoir C, Jeanna McCuaig, Blayney J, Bosdet I, Treacy R, Esther Darder, Ando J, Luc Dehaspe, García-Casado Z, Duffy J, Harkin D, Z Kote-Jarai, Kasamatsu T, Ulf Kristoffersson, Membrez, Priston M, Noreau-Heisz D, Trivedi A, Begoña Graña, Ghadirian P, Ashuryk O, Consol López, Wenzel L, Vogel R, Joseph G, Poll A, Kennedy R, Patton S, Pérez C, Mónica Cornet, Panighetti A, Cassart P, Burke K, Mes-Masson A, Llacuachaqui M, Marc Tischkowitz, Wong N, Arcand S, Kotsopoulos J, Meschino W, Hall A, Marles S, Docking R, Haroun I, Marie Plante, Rachel Laframboise, Daniel Sinnett, Luce J, Sekiguchi I, Edenir Inêz Palmero, de Winter J, Christopher J. Lord, Hamel N, Pruski-Clark J, Lee D, Rusnak A, Carson N, Marta Santamariña, Knoppers B, Oakhill K, Bruce R. Rosen, Pierre O. Chappuis, Bruce Poppe, Stanislaw C, Catts Z, Brood M, van der Wall E, Yip C, Christine Walsh, Hoodfar E, Pressman A, Andrulis I, Alicia Barroso, D. Leongamornlert, Gillian Mitchell, Akira Hirasawa, Shen Z, Sameer Parpia, Horgan M, van Echtelt J, Chun K, Lubinski J, Rebecca Sutphen, Terespolsky D, Richard D, McDyer F, Floquet A, Lambo R, Bathurst L, Brown G, Kidd M, Nicolas Sevenet, Mourits M, Vencken P, Tatiana Popova, Garcia N, Armel S, van Amstel H, Valentini A, Ellen Warner, Hofland N, Hanna D, Kim J, Osann K, Enmore M, Loranger K, Sulivan I, J. Oliveira, Meijers H, Jansen R, Edmundo Carvalho Mauad, Kirkpatrick R, Danilo V Viana, Ian G. Campbell, Mil S, E J Sawyer, J. Balmaña, Samra Turajlic, Graham G, Alonso C, Inanc Birol, Sinclair F, van Tuil M, Pascual Bolufer, Micheli R, Andrew R. Green, Junyent N, Whittaker J, Monnerat C, Rhéaume J, Livingston D, Chan S, L. Ramadan, Lee R, Katarzyna Durda, De Leeneer K, Grados C, Côté C, Kyle B. Matchett, Robert Winqvist, Bonner D, Brunella Pilato, Mohd Taib N, Judy Garber, Kleiderman E, Murakami S, Sharifi N, Kimberley Hill, Desbiens C, Robert Royer, Jasperson K, Hsieh S, De Summa S, Dominique Stoppa-Lyonnet, de Lima J, Stuart McIntosh, Shakeri M, Wendy Kohlmann, Albert-Green A, de Hullu J, Pasick R, Avard D, Pathania S, van der Groep P, Laura Fachal, Bruno Zeitouni, Susan M. Domchek, Davey S, Richard Marais, Powell C, Hans J. J. P. Gille, Greenberg R, Kamata H, Cina, Gaarenstroom K, Lakhal Chaieb M, Kavanagh L, Gaelle Benais-Pont, Sun P, Jansen L, Matthew Parker, Barjhoux L, Russ H, Simon J. Furney, Willems A, Robb L, David E. Goldgar, Young S, Natalia Campacci, Mark G. Thomas, Doug Easton, Klugman S, Barrault M, Calvo N, Adriana C. Flora, Littell R, Narod S, Fragoso, N. Bosch, Finch A, Paul M. Wilkerson, Teo S, Tomasz Huzarski, Manuel Salto-Tellez, Moseley M, Davis S, Olga M. Sinilnikova, Iturbe A, Joan Brunet, Tierney M, Tsai E, Navarro de Souza A, Leclerc M, Lorenzo Manti, Gutiérrez-Enríquez S, Milewski B, Simon S. McDade, Kaplan C, Buckley N, Eva Esteban-Cardeñosa, Richter S, Shimizu C, Li J, Elena Castro, Iwanka Kozarewa, Harley I, Atocha Romero, Carlos E. Andrade, Carole Verny-Pierre, Barouk E, Vian D, Montserrat Baiget, Chan J, Sandra Bonache, Andrew Y Shuen, van der Merwe N, Kaklewski K, Mohar A, Tamura C, Heale E, Rooyadeh M, van Asperen C, Gemma Llort, Alan Mackay, Denroche R, Seelaus C, Zbuk K, McCluggage W, van der Luijt R, Maaike P.G. Vreeswijk, Edelweiss M, Crossan G, Arseneau J, Ambus I, Verheul H, Rodrigo Augusto Depieri Michelli, Juul T. Wijnen, Gross-Lester J, Britta Weigelt, Pedro Pérez-Segura, Richard A. Moore, Cornelissen C, Larouche G, McAlpine J, Daniel Nava Rodrigues, Trim L, Furnival J, Elser C, Muszyńka M, Adriana Lasa, Tuya Pal, Greuter. M, Ng K, Dorval M, Bresee C, Reimnitz G, Gaëtan MacGrogan, Perry Maxwell, Barnadas A, Hwang E, Powell B, Knapke S, Griskevicius. L, Alvarez R, Mester J, Anne-Bine Skytte, Eladio Velasco, Vidal S, Australie K, Leunen K, Ben-Yishay M, Van Houdt J, Phuah S, Amy E Taylor, Pinto R, Fonseca T, Champine M, Gammon A, Hollema H, Menko F, Feng B, David Olmos, Chong G, Tomasz Byrski, Patrick J. Morrison, Gregoire J, André Lopes Carvalho, Don B. Plewes, Rabeneck L, Carrol J, Alan Ashworth, Terlinge A, A Jakubowska, Odette Mariani, Setareh Moghadasi, Reitsma W, Rothenmund H, Herrera L, Anna Tenés, Angel Izquierdo, Asunción Torres, Stawicka M, Goh C, Hirst M, Drummond J, Osorio A, Ostrovsky R, Jeffrey N. Weitzel, Gareth W. Irwin, Fehniger J, Sugano K, Spriggs E, Dęniak T, Volenik A, Thorne H, Piccinin C, Amie Blanco, Jinno H, Robert A. Holt, Stephen B. Fox, Julia J. Gorski, Gilpin C, Herschorn S, Vega A, E. Page, Hamet P, McKenna D, Fabrice Bonnet, Yoshida T, Kienan I. Savage, Petzel S, Elizabeth Bancroft, Schneider S, Warwick L, Stewart S, William D. Foulkes, Colizza K, Bell K, Demsky R, Malgorzata Tymrakiewicz, Caldés T, Fons G, Bowen D, Côté S, Clouston D, Kitagawa Y, Gordon Glendon, Jenny Lester, Kinney A, Nelson E, Silke Hollants, Macrae L, Cajal T, Andrew J. Mungall, Ferrell B, Creighton B, Bressler L, Uy P, Makishima K, Haffaf Z, Ramūnas Janavičius, Einstein G, Zakalik D, Chiarelli A, Cantu D, Croce S, Kalloger S, Lin F, Ian O. Ellis, Benedito Mauro Rossi, R A Wilkinson, Mulligan J, Murphy J, Vadaparampil S, Smith E, Slangen B, Loiselle C, Iqbal J, Palma L, Cooper K, Jorge S. Reis-Filho, Chen. L, Quinten Waisfisz, Haneda E, Banks P, Vermeulen K, Visser B, Montalbán G, McCabe N, Honeyford J, Naseri S, Ng J, Ali A, Sandrine Viala, Mensa I, Kamarainen O, Guerra C, Mazzola E, David A. Schwartz, Marjanka K. Schmidt, Simon R, Fergus J. Couch, Margreet G. E. M. Ausems, Anne Vincent-Salomon, Olinski R, Zewald R, Moreno R, Semple J, McPherson J, Lamers E, Kharbanda A, Kessler L, Biemans D, Au A, Bordeleau L, Jean Feunteun, Mar Infante, Mullan P, Rudaitis, Molenda A, Rachael Natrajan, Pawar, Boman B, Kok T, Andrew A. Brown, Geller M, Monfared N, Bart J, Murata P, Crawford N, Butterfield Y, Bargalló J, Katherine L. Tucker, Cook-Wiens G, Rhodes A, Elodie Manié, Rubio E, Oram L, Shandiz F, Hayden R, Crawford B, Parmigiani G, Harkin P, Müller C, Grant M, Maryou B. Lambros, Thong M, Grzegorz Sukiennicki, Wouts J, Haddock P, Ramon y Cajal T, Kenneth C. Anderson, Michel Longy, Batiste W, Carroll J, Matte C, Hojyo T, Zhao Y, Caroline Seynaeve, Wai P, Simard J, Hurley K, Bolton D, Karlan B, Javier Benítez, Miriam Masas, Tołczko-Grabarek A, de Dueñas E, Geneviève Michils, Moncoutier, Nancy Uhrhammer, MacDonald D, Keyserlingk J, Osher D, Gilks C, Christopher T. Elliott, Scharf L, Gabram-Mendola S, Grondin K, Dohany L, van Diest P, Joris Vermeesch, Jan C. Oosterwijk, M’Baïlara K, DePuit M, Jacek Gronwald, Stefania Tommasi, de la Hoya M, Bouchard K, Black L, Lui M, Soucy P, Rosalind A. Eeles, Gert Matthijs, Graham T, Andrea Eisen, Bacha O, Alvaro N.A. Monteiro, Yoon S, Caron T, Smith D, Marc-Henri Stern, Hampson E, Kurz R, Gaasbeek W, Mundt E, Angela Velasco, Quinn J, Jocelyne Chiquette, Marquez T, Adam B. Murphy, Bakker J, Neus Gadea, Anita Grigoriadis, Aoki D, Dean S, Looi L, Paradiso A, Agostina Stradella, K. Govindasami, Lovell N, Eva Tomiak, Siesling S, Belanger M, Feilotter H, Knight J, Emmanuel Barillot, Huang M, Raquel Andrés, Kang P, Somerman C, Gackowski D, Rimel B, Nakamura S, McClellan K, Barrros E, Henriette Roed Nielsen, Rui Manuel Reis, Greening S, Ayme A, Carmen Guillen, de Vries E, and Katarzyna Jaworska

Subjects
Oncology, Education and Communication, medicine.medical_specialty, endocrine system diseases, medicine.diagnostic_test, business.industry, Psycho-Oncology, medicine.disease, Meeting Abstracts, Transcriptome, Basic Research, Clinical Management, Germline mutation, Breast cancer, Applied Research, Internal medicine, Mutation (genetic algorithm), medicine, Genetic Counselling, Human genome, skin and connective tissue diseases, business, Ovarian cancer, Comparative genomic hybridization, Fluorescence in situ hybridization
Abstract

Background: Germline mutation screening of BRCA1 and BRCA2 genes is performed in suspected familial breast cancer cases, but a causative mutation is found in only 30% of patients. The development of additional methods to identify good candidates for BRCA1 and BRCA2 analysis would therefore increase the efficacy of diagnostic mutation screening. With this in mind, we developed a study to determine molecular signatures of BRCA1—or BRCA2—mutated breast cancers. Materials and Methods: Array-cgh (comparative genomic hybridization) and transcriptomic analysis were performed on a series of 103 familial breast cancers. The series included 7 breast cancers with a BRCA1 mutation and 5 breast cancers with a BRCA2 mutation. The remaining 91 cases were obtained from 73 families selected on the basis of at least 3 affected first-degree relatives or at least 2 affected first-degree relatives with breast cancer at an average age of 45 years. Array-cgh analyses were performed on a 4407 BAC-array (CIT-V8) manufactured by IntegraGen. Transcriptomic analyses were performed using an Affymetrix Human Genome U133 Plus 2.0 chip. Results: Using supervised clustering analyses we identified two transcriptomic signatures: one for BRCA1-mutated breast cancers consisting of 600 probe sets and another for BRCA2-mutated breast cancers also consisting of 600 probes sets. We also defined cgh-array signatures, based on the presence of specific genomic rearrangements, one for BRCA1-mutated breast cancers and one for BRCA2-mutated breast cancers. Conclusions: This study identified molecular signatures of breast cancers with BRCA1 or BRCA2 germline mutations. Genes present in these signatures could be exploited to find new markers for such breast cancers. We also identified specific genomic rearrangements in these breast cancers, which could be screened for in a diagnostic setting using fluorescence in situ hybridization, thus improving patient selection for BRCA1 and BRCA2 molecular genetic analysis.

Published
2009

37. Abstract P3-09-05: Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

Author

Stjepanovic, N, primary, Kim, RH, additional, Wilson, M, additional, Mandilaras, V, additional, Berman, H, additional, Amir, E, additional, Cescon, D, additional, Elser, C, additional, Randall Armel, S, additional, McCuaig, J, additional, Volenik, A, additional, Demsky, R, additional, Chow, H, additional, Misyura, M, additional, Wang, L, additional, Oza, AM, additional, Kamel-Reid, S, additional, Stockley, T, additional, and Bedard, PL, additional

Published
2017
Full Text
View/download PDF

39. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

Author

Kotsopoulos, J, Lubinski, J, Gronwald, J, Cybulski, C, Demsky, R, Neuhausen, Sl, Kim Sing, C, Tung, N, Friedman, S, Senter, L, Weitzel, J, Karlan, B, Moller, P, Sun, P, Narod, Sa, Hereditary Breast Cancer Clinical Study Group: Lynch HT, Singer, C, Eng, C, Mitchell, G, Huzarski, T, Mccuaig, J, Hughes, K, Mills, G, Ghadirian, P, Eisen, A, Gilchrist, D, Blum, Jl, Zakalik, D, Pal, T, Daly, M, Weber, B, Snyder, C, Fallen, T, Chudley, A, Lunn, J, Donenberg, T, Kurz, Rn, Saal, H, Garber, J, Rennert, G, Sweet, K, Gershoni Baruch, R, Rappaport, C, Lemire, E, Stoppa Lyonnet, D, Olopade, Oi, Merajver, S, Bordeleau, L, Cullinane, Ca, Friedman, E, Mckinnon, W, Wood, M, Rayson, D, Meschino, W, Mclennan, J, Costalas, Jw, Reilly, Re, Vadaparampil, S, Offit, K, Kauff, N, Klijn, J, Euhus, D, Kwong, A, Isaacs, C, Couch, F, Manoukian, S, Byrski, T, Elser, C, Panchal, S, Armel, S, Nanda, S, Metcalfe, K, Poll, A, Rosen, B, Foulkes, Wd, Rebbeck, T, Ainsworth, P, Robidoux, A, Warner, E, Maehle, L, Osborne, M, Evans, G, Pasini, Barbara, Ginsburg, O, Cohen, S, Bohdan, G, Jakubowska, A, and Little, J.

Subjects
Adult, Heterozygote, Cancer Research, medicine.medical_specialty, Breast Neoplasms, Breast cancer, breast cancer, Risk Factors, medicine, Humans, Genetic Association Studies, Gynecology, Oral contraceptives, BRCA1 Protein, Obstetrics, business.industry, Age Factors, Case-control study, Cancer, Odds ratio, Middle Aged, medicine.disease, BRCA mutations, Oncology, Family planning, Case-Control Studies, Pill, Relative risk, Mutation, Female, Ovarian cancer, business, Contraceptives, Oral
Abstract

It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case-control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 % confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 % CI 1.20-1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 % CI 0.99-1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 % CI 1.14-1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 % with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 % CI 1.03-1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 % CI 0.79-1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25.

Published
2014

43. Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation

Author

Senst, N, Llacuachaqui, M, Lubinski, J, Lynch, H, Armel, S, Neuhausen, S, Ghadirian, P, Sun, P, Narod, Sa, Hereditary Breast Cancer Study Group: Panchal, S, Rosen, B, Demsky, R, Foulkes, Wd, Kim Sing, C, Singer, C, Short, T, Senter, L, Sweet, K, Tung, N, Ainsworth, P, Eisen, A, Gilchrist, D, Bordeleau, L, Olopade, Oi, Karlan, B, Kurz, R, Couch, F, Manoukian, S, Daly, M, Saal, H, Mckinnon, W, Wood, M, Elser, C, Eng, C, Weitzel, J, Mclennan, J, Lemire, E, Fallen, T, Kaklamani, V, Stoppa Lyonnet, D, Isaacs, C, Rayson, D, Ginsburg, O, Chudley, A, Pasini, Barbara, Zakalik, D, Cullinane, Ca, Pal, T, Vadaparampil, S, Friedman, S, Meschino, W, Moller, P, Maehle, L, Valentini, A, Ragone, A, Poll, A, and Nanda, S.

Subjects
Adult, BRCA2 Protein, Risk, parental origin, BRCA1 Protein, Inheritance Patterns, Breast Neoplasms, Middle Aged, BRCA mutations, Pedigree, Young Adult, breast cancer, Mutation, Humans, Female, Prospective Studies, Aged, Proportional Hazards Models
Abstract

The objective is to estimate the risk of breast cancer in women who carry a deleterious BRCA1 or BRCA2 mutation, according to parental origin of mutation. We conducted a cohort study of women with a BRCA1 mutation (n = 1523) or BRCA2 mutation (n = 369) who had not been diagnosed with breast or ovarian cancer. For each woman, the pedigree was reviewed and the origin of the mutation was assigned as probable paternal or maternal. The hazard ratio (HR) for developing breast cancer in the follow-up period was estimated for women with a paternal mutation compared to a maternal mutation. The risk of breast cancer was modestly higher in women with a paternal BRCA1 mutation compared to women with a maternal BRCA1 mutation (HR = 1.46; 95% CI = 0.99-2.16) but the difference was not significant (p = 0.06). The parental mutation origin did not affect the risk in women with a BRCA2 mutation. Our results are consistent with the hypothesis that there is an increased risk of breast cancer among women with a paternally inherited BRCA1 mutation compared to a maternally inherited mutation. However, the data are not sufficiently compelling to justify different screening recommendations for the two subgroups.

Published
2012

44. Genetic testing forBRCA1andBRCA2in the Province of Ontario

Author

Finch, A., primary, Wang, M., additional, Fine, A., additional, Atri, L., additional, Khalouei, S., additional, Pupavac, M., additional, Rosen, B., additional, Eisen, A., additional, Elser, C., additional, Charames, G., additional, Metcalfe, K., additional, Chang, M.C., additional, Narod, S.A., additional, and Lerner-Ellis, J., additional

Published
2015
Full Text
View/download PDF

46. Human gamma/delta T-cell response to Listeria monocytogenes protein components in vitro

Author

Munk, M E, Elser, C, and Kaufmann, S H

Subjects
Virulence, Bacterial Toxins, Serine Endopeptidases, Cell Culture Techniques, Receptors, Antigen, T-Cell, gamma-delta, Lymphocyte Activation, Listeria monocytogenes, Hemolysin Proteins, Kinetics, Bacterial Proteins, T-Lymphocyte Subsets, Humans, Endopeptidase K, Heat-Shock Proteins, Research Article
Abstract

Listeria monocytogenes is a facultative intracellular pathogen that replicates inside mononuclear phagocytes and induces specific cellular immunity. Listeriosis encompasses many clinical syndromes and meningitis is the most frequent clinical manifestation. Human alpha/beta and gamma/delta T cells have been shown to respond to L. monocytogenes antigens and to play an important role in resistance against listerial infection. We investigated the nature of listerial ligands and the influence of the major virulence factor, listeriolysin (hly), on the stimulation of human gamma/delta T cells from healthy individuals. We found that a listerial somatic protein ligand, which is sensitive to proteinase treatment, stimulated gamma/delta T cells in vitro; the majority of Listeria-responsive gamma/delta T cells expressed V gamma 9V delta 2 T-cell receptor chains and human leucocyte antigen-DR molecules; gamma/delta T-cell responses to hly+ and hly- Listeria strains were comparable; L. monocytogenes strains of different virulence stimulated gamma/delta T cells equally. Thus, protein components of L. monocytogenes unrelated to virulence activate human gamma/delta T cells in vitro.

Published
1996

50. Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT)

Author

Liu, C. S., primary, Elser, C., additional, Huang, S., additional, Pond, G. R., additional, O'Sullivan, B., additional, Chen, E. X., additional, Waldron, J. N., additional, Goldstein, D., additional, Siu, L. L., additional, and Kim, J., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results